This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Melanoma	Cyclic adenosine monophosphate (cAMP); cell division cycle 25B (CDC25B); melanocortin 1 receptor (MC1R)	Cell culture studies suggest targeting the MC1R-cAMP-CDC25B signaling pathway could help treat melanoma. In a panel of human melanoma cell lines, activators of MC1R or cAMP signaling inhibited cell cycle progression compared with vehicle. In the cell lines, MC1R- and cAMP-mediated inhibition of cell cycle progression was dependent on inhibitory phosphorylation of CDC25B. Next steps could include screening for and evaluating pharmacological inhibitors of CDC25B in melanoma models. SciBX 6(33); doi:10.1038/scibx.2013.888 Published online Aug. 29, 2013	Patent and licensing status unavailable	Lyons, J. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Aug. 1, 2013; doi:10.1073/pnas.1201917110 Contact: Frank McCormick, University of California, San Francisco, Calif. e-mail: mccormick@cc.ucsf.edu